OLIGO METS IN RCC: AN ITALIAN MULTIDISCIPLINARY VISION FOR A WORLDWIDE PATH
Corso RESIDENZIALE ECM
In presenza - Sede Cogressuale: SALONE MORIELLO- OSPEDALE CARDARELLI - VIA ANTONIO CARDARELLI, 9 - Napoli
Responsabile Scentifico: Sarah Scagliarini
Date del corso: 9 dicembre 2026 ECM
Crediti ECM: 7
10 dicembre: 09:00 - 13:00 (FUORI ECM) - HOTEL PARADISO - Napoli
Titolo evento FUORI ECM: BUILDING AN OLIGO-RCC PATHWAY: FROM A NATIONAL MULTIDISCIPLINARY MEETING TO A GLOBAL PROPOSAL
Razionale
In recent years, we have witnessed a major revolution in renal cell carcinoma, spanning from localized to metastatic disease. Thanks to randomized clinical trials, starting with first-line immuno-combinations (IO+IO and IO+TKI) and extending to recent adjuvant immunotherapy with pembrolizumab, a wealth of data and real-world evidence has outlined clear therapeutic strategies aligned with clinical guidelines. However, optimizing these systemic therapies relies heavily on a multidisciplinary approach and the integration of radiotherapy, surgery, and locoregional treatments such as thermo- and cryoablation. Another breakthrough in recent months involves patients with renal cell carcinoma and VHL disease, where belzutifan has offered the possibility of avoiding multiple surgical resections. Nevertheless, several grey areas remain poorly defined from diagnosis to treatment, particularly regarding OLIGOMETASTASIS in RCC.
This national meeting, bringing together leading experts across all relevant disciplines, aims to explore this phase of kidney cancer, both after localized disease and during systemic therapy for metastatic disease, covering everything from biomarkers and biology to the integration of surgery, radiotherapy, and ablation. Special focus will be given to the emerging area of oligoprogression in VHL-mutated patients to highlight the clinical benefits of belzutifan therapy.
The meeting will delve into the management of oligometastatic disease during first-line therapy, which remains the most critical phase in the natural history of these patients. Oligoprogression following surgery, with or without adjuvant therapy, will also be examined. Moving from current evidence to future research perspectives, the ultimate goal is to establish a clear decision-making algorithm for patients affected by OLIGOPROGRESSION in Renal Cell Carcinoma.
PROGRAMMA ECM - 09 DICEMBRE 2026
10:30 – OPENING SESSION
Introduction: Antonio D’Amore
Objectives: Sarah Scagliarini
Agenda: Riccardo Campi
11:00 – EMPOWERING PATIENTS WITH OLIGOPROGRESSIVE RCC
Chair persons: Sarah Scagliarini, ANTURE (Associazione Nazionale Tumore del Rene), Giacomo Cartenì
- The Patient Story – Gaetano Rivezzi
11:30 – OLIGO-BOARD: THE BETTER SOLUTION FROM A RCC TEAM
Chair persons: Ferdinando Riccardi, Giovanni Di Lauro
Presenter: Mimma Rizzo
Panelists: Livio Puglia, Marilena Di Napoli, Marco Fabiano, Laura Turchetta, Marco Di Serafino, Amelia Biasucci, Vincenzo Ravo, Francesco Giurazza
12:00 – OLIGOPROGRESSION: THE VHL LIGHT-BULB MOMENT
Chair persons: Lorena Incorvaia, Paola D’Ambrosio, Annalisa Guida
-
Clonal architecture and genomic evolution of VHL-associated ccRCC revealed by multi-region whole genome sequencing – Francesca Corea
-
Oncologic-vision on VHL Syndrome and HIF 1 α inhibition – Antonio Cigliola
12:30 – OLIGORCC RESEARCH AND PROSPECTIVE TRIALS
Chair persons: Ciro Franzese, Sebastiano Buti, Roberto Iezzi
-
An International Multidisciplinary Consensus Statement on Oligometastatic Renal Cell Carcinoma – Savio Domenico Pandolfo
-
Pe-Pe trial – Chiara Ciccarese
-
Kairos trial – Lorena Incorvaia
-
Omega-RCC trial – Fortuna Migliaccio
13:00 – DISCUSSION
13:30 – LUNCH
14:30 – OLIGOPROGRESSION IN RCC: FROM TUMOR BIOLOGY TO MOLECULAR MONITORING AND RESISTANCE
Chair persons: Luigi Formisano, Cinzia Conteduca, Brigida Maiorano
-
Mechanism of resistance and Therapeutic Opportunities – Laura Marandino
-
Kim-1 and others biomarkers in RCC – Liliana Ascione
-
Multidimensional Liquid Biopsy in RCC: are we ready for prime time? – Umberto Malapelle
-
ctDNA as turning point in RCC strategy? – Andrè Andraz La Cruz
16:00 – OLIGO-DEBATE: GUIDELINES AND SCIENTIFIC EVIDENCE
Chair persons: Sarah Scagliarini, Franco Orsi, Sebastiano Buti
Panelists: Giulia Marvaso, Riccardo Campi, Carlotta Palumbo, Laura Crocetti, Maria Giuseppa Vitale
16:30 – OLIGO-CROSS FIRE
Chair persons: Luigi Formisano, Laura Crocetti, Savio Domenico Pandolfo
-
Oligo-Mets Diagnosis – Laura Evangelista
-
Renal Relapse – Carlotta Palumbo vs Franco Orsi vs Ciro Franzese
-
Lung Relapse – Luca Nicosia vs Roberto Iezzi vs Gianluca Guggino
-
Liver and Bone Relapse – Brigida Maiorano vs Francesco Giurazza vs Giulia Marvaso
18:00 – WHEN NOT TO TREAT WITH MDT
Ciro Franzese, Cristian Lolli
18:20 – SHARED SHORT STORY OF OLIGO-CASE DURING FIRST LINE TREATMENT
Chair persons: Davide Bosso, Luca Nicosia
Presenters: Fabrizio Di Costanzo & Pierpaolo Dragonetti, Simone Rocco Flammia & Giuseppe Neola
19:00 – CONCLUSION
__________________________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________________________
Italian Medical Research
Provider ECM n°1344 accreditato presso il Ministero della Salute - Age.na.s
Per qualsiasi comunicazione e/o supporto:
- 0824 23156
- italianmr.com
- assistenza@italianmr.com
- Leggi le FAQ
Per consultare la nostra lista di Corsi ECM: